Recent Company News

• 10:02 AM ET Feb 17, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (210 total)

• 09:53 AM ET Feb 05, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (208 total)

• 03:09 PM ET Feb 03, 2026
  

  Bicycle Therapeutics trading lower following company's leadership change announcement ($5.98, -0.52)

• 07:05 AM ET Feb 03, 2026
  

  Bicycle Therapeutics announces leadership transitions ($6.49, 0.00)

• 12:17 PM ET Jan 16, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX (1.4%) to $15.62; S&P 500 +0.2% to $6,955.87

• 07:17 AM ET Jan 12, 2026
  

  Bicycle Therapeutics notes strategic priorities for 2026 ($6.64, 0.00)

• 11:34 AM ET Jan 02, 2026
  

  Novel Modalities Drive $668B Precision Oncology Expansion

• 11:03 AM ET Dec 29, 2025
  

  Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation

• 11:03 AM ET Dec 28, 2025
  

  Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

• 12:58 AM ET Dec 27, 2025
  

  Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation